Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just like clockwork....a green Friday followed by a week of red....lol
Now you are starting to see the light!
Great reply and explanation! Thanks Reaper!
Better start praying....don't remember anything remotely close to .19 or higher since September 15th...lol
.20 soon???? Thought this pos was going to be .50 at the end of September...lol. Oh, guess you didn't state September 2017...lol
Right there with you on that. Sure glad I sold when it was .165....lol
So, what "news" is everyone waiting for? Its obvious that ticker is going to change so that is not going to be "news". Anything else other than the obvious?
Agree 100%...sit back and enjoy the show. Filing will show up in 3-4 days.
Reason NOT to buy AEPP/Oncolix. November 1st right around the corner. Thus begins the convertible note interest payments:
Convertible Notes
In August 2017, the Company issued convertible notes to the investors in an aggregate principal amount of $4,190,463 for a purchase price of $3,561,894. The Convertible Notes bear interest at a rate of 10% per annum, payable quarterly on November 1, 2017, February 1, 2018, and May 1, 2018 and thereafter, on a monthly basis until maturity. The interest is payable in cash or, at the option of the Company, subject to compliance with Equity Conditions (as defined below), in fully tradable Company Common Stock at the lesser of the then conversion price and a 25% discount to the average of the five lowest closing bid prices for the twenty trading days prior to the interest payment date. The final maturity of the Convertible Notes is November 1, 2018, but commencing on May 1, 2018 and on the first day of each month thereafter until maturity, we are required to redeem an amount of the Convertible Notes equal to 1/7th of the original principal amount, plus 10% of such monthly redemption amount as a bonus. The principal payments shall be made in cash or, subject to the satisfaction of Equity Conditions, in our Common Stock valued at the lesser of the then conversion price and a 25% discount to the average of the five lowest closing bid prices for the twenty trading days prior to the amortization date.
The Convertible Notes are convertible at the option of the Purchasers at a conversion price equal to the lesser of (i) $0.075 per share of our Common Stock, (ii) 75% of the 10-day average closing bid price of our Common Stock for the period prior to the filing of a registration statement as described below (subject to a floor of $0.0375 per share), and (iii) 75% of the 10-day average closing bid price of our Common Stock for the 10-day period prior to the effective date of the registration statement (subject to a floor of $0.0375 per share). The Convertible Notes contain customary anti-dilution protection, including full-ratchet anti-dilution adjustments in the event of certain dilutive issuances (that adjust both conversion price and share amounts to be issued upon conversion). In the event of a closing of an $8 million financing in connection with a change in listing of our Common Stock to Nasdaq or the NYSE, the Convertible Notes shall be subject to mandatory conversion into our Common Stock at a 30% discount to the offering price. We shall be required to offer to prepay in cash the aggregate principal amount of the Convertible Notes at 120% of the principal amount thereof plus any unpaid accrued interest to the date of repayment, at maturity, on the sale of substantially all of our assets, upon a change of control, upon a qualified offering, or upon a “fundamental transaction” (tender offer, reclassification, sale of substantially all assets and merger); in such an event, the Purchasers shall have the right to convert the Convertible Notes prior to the date of any such prepayment. The Convertible Notes contain standard negative covenants customary for transactions of this type. The events of default are also customary for transactions of this type, including default in timely payment of principal or interest, failure to observe or perform any covenant or agreement contained in the Convertible Note and Transaction Documents (including the Registration Rights Agreement), the commencement of bankruptcy or insolvency proceedings, failure to timely deliver conversion shares underlying the Convertible Notes, failure to timely file Exchange Act filings, and failure to satisfy certain Equity Conditions.
Source:
14C dated 9/6/17
https://www.sec.gov/Archives/edgar/data/1584137/000147793217004337/aepp_def14c.htm
Low float, highly volatile stock...sitting on a timebomb IMO
It's Friday and you know what that means???? Fake close day!!! Sometime in the last hour of trading pps will go up....lol
Yes, I'm sure things will change. Oncolix will probably be .00001 a share, Redman and Payne will be in prison, Prolanta will have failed clinical trials, etc....lol
Very impressed that this scam was such a cheap investment. $315,000 to purchase AEPP, $57,926 for fees to file SEC filings promptly and file them on time to make everything look legit, get some high school kid to create a website for free, $12,000 for some radio time with Small Cap Voice, transfer useless patents into their name, give 3 people $20 each to register as clinical trial patients, on and on.
Nice Oncolix website!!! Nice websites don't make shareholders richer. Proven results and a product with some value to others does. Oncolix has neither. Lot of fluff, but that's all it is. Oh, and by the way, don't tell me to wait 2 years or a few months for things to change, it won't.
Want to know why the stock price is not going up???? 20 trading days prior to November 1st just started. Investors will drive price down between now and November 1st so they maximize their interest payment (which will likely be in the form of shares of common stock since Oncolix has no cash).
"The interest is payable in cash or, at the option of the Company, subject to compliance with Equity Conditions (as defined below), in fully tradable Company Common Stock at the lesser of the then conversion price and a 25% discount to the average of the five lowest closing bid prices for the twenty trading days prior to the interest payment date."
Source:
14C Page 11
https://www.sec.gov/Archives/edgar/data/1584137/000147793217004337/aepp_def14c.htm
Wrong again. Filings clearly state interest payable ever 3 months starting November 2017 and not restricted.
LOW FLOAT NOT FOR MUCH LONGER. COMMON STOCK WILL BE ISSUED NOVEMBER 1ST. EXPECT 2,000,000-3,000,000 SHARES TO BE ISSUED AND DUMPED SHORTLY AFTER.
Convertible Notes
In August 2017, the Company issued convertible notes to the investors in an aggregate principal amount of $4,190,463 for a purchase price of $3,561,894. The Convertible Notes bear interest at a rate of 10% per annum, payable quarterly on November 1, 2017, February 1, 2018, and May 1, 2018 and thereafter, on a monthly basis until maturity. The interest is payable in cash or, at the option of the Company, subject to compliance with Equity Conditions (as defined below), in fully tradable Company Common Stock at the lesser of the then conversion price and a 25% discount to the average of the five lowest closing bid prices for the twenty trading days prior to the interest payment date. The final maturity of the Convertible Notes is November 1, 2018, but commencing on May 1, 2018 and on the first day of each month thereafter until maturity, we are required to redeem an amount of the Convertible Notes equal to 1/7th of the original principal amount, plus 10% of such monthly redemption amount as a bonus. The principal payments shall be made in cash or, subject to the satisfaction of Equity Conditions, in our Common Stock valued at the lesser of the then conversion price and a 25% discount to the average of the five lowest closing bid prices for the twenty trading days prior to the amortization date.
The Convertible Notes are convertible at the option of the Purchasers at a conversion price equal to the lesser of (i) $0.075 per share of our Common Stock, (ii) 75% of the 10-day average closing bid price of our Common Stock for the period prior to the filing of a registration statement as described below (subject to a floor of $0.0375 per share), and (iii) 75% of the 10-day average closing bid price of our Common Stock for the 10-day period prior to the effective date of the registration statement (subject to a floor of $0.0375 per share). The Convertible Notes contain customary anti-dilution protection, including full-ratchet anti-dilution adjustments in the event of certain dilutive issuances (that adjust both conversion price and share amounts to be issued upon conversion). In the event of a closing of an $8 million financing in connection with a change in listing of our Common Stock to Nasdaq or the NYSE, the Convertible Notes shall be subject to mandatory conversion into our Common Stock at a 30% discount to the offering price. We shall be required to offer to prepay in cash the aggregate principal amount of the Convertible Notes at 120% of the principal amount thereof plus any unpaid accrued interest to the date of repayment, at maturity, on the sale of substantially all of our assets, upon a change of control, upon a qualified offering, or upon a “fundamental transaction” (tender offer, reclassification, sale of substantially all assets and merger); in such an event, the Purchasers shall have the right to convert the Convertible Notes prior to the date of any such prepayment. The Convertible Notes contain standard negative covenants customary for transactions of this type. The events of default are also customary for transactions of this type, including default in timely payment of principal or interest, failure to observe or perform any covenant or agreement contained in the Convertible Note and Transaction Documents (including the Registration Rights Agreement), the commencement of bankruptcy or insolvency proceedings, failure to timely deliver conversion shares underlying the Convertible Notes, failure to timely file Exchange Act filings, and failure to satisfy certain Equity Conditions.
Source:
14C dated 9/6/17
https://www.sec.gov/Archives/edgar/data/1584137/000147793217004337/aepp_def14c.htm
Want to know why the stock has suddenly increased in price? 20 trading days prior to November 1st just started. Investors will drive up the price between now and November 1st so they maximize their interest payment (which will likely be in the form of common stock since Oncolix has no cash) and then will dump their stock.
"The interest is payable in cash or, at the option of the Company, subject to compliance with Equity Conditions (as defined below), in fully tradable Company Common Stock at the lesser of the then conversion price and a 25% discount to the average of the five lowest closing bid prices for the twenty trading days prior to the interest payment date."
Source:
14C Page 11
https://www.sec.gov/Archives/edgar/data/1584137/000147793217004337/aepp_def14c.htm
Want to know why investors will flee after ticker change??? November 1st right around the corner. Thus begins the convertible note interest payments:
Convertible Notes
In August 2017, the Company issued convertible notes to the investors in an aggregate principal amount of $4,190,463 for a purchase price of $3,561,894. The Convertible Notes bear interest at a rate of 10% per annum, payable quarterly on November 1, 2017, February 1, 2018, and May 1, 2018 and thereafter, on a monthly basis until maturity. The interest is payable in cash or, at the option of the Company, subject to compliance with Equity Conditions (as defined below), in fully tradable Company Common Stock at the lesser of the then conversion price and a 25% discount to the average of the five lowest closing bid prices for the twenty trading days prior to the interest payment date. The final maturity of the Convertible Notes is November 1, 2018, but commencing on May 1, 2018 and on the first day of each month thereafter until maturity, we are required to redeem an amount of the Convertible Notes equal to 1/7th of the original principal amount, plus 10% of such monthly redemption amount as a bonus. The principal payments shall be made in cash or, subject to the satisfaction of Equity Conditions, in our Common Stock valued at the lesser of the then conversion price and a 25% discount to the average of the five lowest closing bid prices for the twenty trading days prior to the amortization date.
The Convertible Notes are convertible at the option of the Purchasers at a conversion price equal to the lesser of (i) $0.075 per share of our Common Stock, (ii) 75% of the 10-day average closing bid price of our Common Stock for the period prior to the filing of a registration statement as described below (subject to a floor of $0.0375 per share), and (iii) 75% of the 10-day average closing bid price of our Common Stock for the 10-day period prior to the effective date of the registration statement (subject to a floor of $0.0375 per share). The Convertible Notes contain customary anti-dilution protection, including full-ratchet anti-dilution adjustments in the event of certain dilutive issuances (that adjust both conversion price and share amounts to be issued upon conversion). In the event of a closing of an $8 million financing in connection with a change in listing of our Common Stock to Nasdaq or the NYSE, the Convertible Notes shall be subject to mandatory conversion into our Common Stock at a 30% discount to the offering price. We shall be required to offer to prepay in cash the aggregate principal amount of the Convertible Notes at 120% of the principal amount thereof plus any unpaid accrued interest to the date of repayment, at maturity, on the sale of substantially all of our assets, upon a change of control, upon a qualified offering, or upon a “fundamental transaction” (tender offer, reclassification, sale of substantially all assets and merger); in such an event, the Purchasers shall have the right to convert the Convertible Notes prior to the date of any such prepayment. The Convertible Notes contain standard negative covenants customary for transactions of this type. The events of default are also customary for transactions of this type, including default in timely payment of principal or interest, failure to observe or perform any covenant or agreement contained in the Convertible Note and Transaction Documents (including the Registration Rights Agreement), the commencement of bankruptcy or insolvency proceedings, failure to timely deliver conversion shares underlying the Convertible Notes, failure to timely file Exchange Act filings, and failure to satisfy certain Equity Conditions.
Source:
14C dated 9/6/17
https://www.sec.gov/Archives/edgar/data/1584137/000147793217004337/aepp_def14c.htm
Newbies beware!!! AEPP shareholders have been holding for months and do not want to go thru another drop like happened recently when AEPP went from .17 to .05!!! Well-known fact that when ticker changes next week many will dump and flee this pos.
Oncolix koolaid is starting to kick in...many investors who drank are starting to believe again this pos can actually reach .20/share...not in our lifetime.
LOL...in August you stated Celgene was going to buy for $5 a share. Now $2 a share??? LOL
Goodbye .0888!!!
Seems to the Friday afternoon Oncolix MO as well as spend money and issue stock to pay for expenses.
Oncolix future destined for dilution. No cash. Incur expenses, issue stock. Incur expenses, issue stock. Incur expenses, issue stock, etc, etc, etc.
Source:
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12314035
With the exception of a couple well-know facts, that is nothing but a list of empty promises and pipe dreams. Especially the part about nobody knows Oncolix exists....lol. They have been around for years. The whole state of Texas and many more know them well.
Does it matter???? Ticker change is not relevant and will not have an impact.
Very impressed that this scam was such a cheap investment. Would have thought it would be way more costly than $57,926 to setup a fake merger, file SEC filings promptly and on time to make everything look legit, change the stock symbol to increase pps, etc. Soon the plug will be pulled.
Source:
10Q page 18
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12314035
Oncolix incurring more costs and doing nothing in the way of research and development of Prolanta per 10Q dated June 30th:
"The Company incurred no revenues or research and development expenses during the six months ended June 30, 2017 and 2016. General and administrative expenses increased by $57,926 between the periods, principally as a result of the costs related to the management of activities by Oncolix (Delaware) and costs associated with the Merger. Oncolix (Delaware) changed $25,924 for compensation costs and $2,000 for occupancy costs to manage the activities of the Company during the three months ended June 30, 2017. In addition, the Company incurred approximately $29,000 in legal expenses in connection with the proposed Merger with Oncolix (Delaware) in the 2017 period. The costs paid by Oncolix (Delaware) ($approximately $52,000) are reflected as a liability of the Company as of June 30, 2017."
Source:
10Q page 18
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12314035
ONCOLIX NOT LOOKING GOOD!!!!
Oncolix required to find other ways to proceed with clinical trials because Greenville Hospital is merging with Palmetto Health!
Greenville Health System is joining forces with Palmetto Health in Columbia, creating the largest health system in South Carolina, officials said Thursday. Chris McMahon/Wochit
http://www.greenvilleonline.com/story/news/2017/08/22/ghs-ceo-mike-riordan-named-one-modern-healthcares-100-most-influential-people/589743001/
Oncolix has no patients for clinical study!
https://clinicaltrials.gov/ct2/show/NCT02534922
Oncolix has no clinical information listed with their largest shareholder Greenville Health Center or Greenville Health System https://www.guidestar.org/profile/30-0300419
Oncolix has worthless patents!
https://assignment.uspto.gov/patent/index.html#/patent/search/resultAssignee?assigneeName=ONCOLIX,%20INC
Oncolix authorized shares increased from 500,000,000 to 950,000,000!
Wen Chen (inventor of Prolanta) no longer associated with Greenville Health System or Oncolix!
Want more, let me know!
AEPP/ONCOLIX NOT LOOKING GOOD!!!!
No patients for clinical study!
https://clinicaltrials.gov/ct2/show/NCT02534922
No clinical trial data!
https://www.ghs.org/healthcareservices/cancer/
Worthless patents!
https://assignment.uspto.gov/patent/index.html#/patent/search/resultAssignee?assigneeName=ONCOLIX,%20INC
Wen Chen (inventor of Prolanta) no longer associated with Oncolix!
Ever notice when Prolanta documents and materials are referred to, and the documents and materials are always 2-3 years old or older. There's a reason for that.
Got any proof that Prolanta has more than 3 patients in clinical trial? Got any proof that Prolanta is not sitting on a shelf in a closet at some lab? If not, then your post is nonsense.
And here's more enlightening news for you, their website lists 3 advisors:
Wen Y. Chen, Ph.D. Inventor
George Peoples, Jr., MD, FACS Chairman of Phase I DSMB
William E. Gannon, Jr., M.D., M.B.A. Chief Regulatory Advisor
Wen Chen is long gone as well as Gannon. Only Peoples is an advisor.
"Don't stop believin, hold on to that feelin"...soon it will all make sense.
There is no denying the fact that there has been more time, effort, and money spent to get filings submitted, doing SCN interviews, attending conferences, and to get exposure on a radio show than there has been time, effort, and money spent to get Prolanta thru clinical trials. BIG RED FLAG!!!
Yep, it's an investment...an investment to pump up this pos.
Interesting news...if Oncolix has no income, where did the $12,000 come from?????
Certainly starting to look as though Oncolix is a scam:
https://clinicaltrials.gov/ct2/show/NCT02534922
No patients for study. No update for almost 6 months.
https://www.ghs.org/healthcareservices/cancer/
Nothing about clinical trials or Prolanta.
https://assignment.uspto.gov/patent/index.html#/patent/search/resultAssignee?assigneeName=ONCOLIX,%20INC
Worthless patents.
Awesome post!!!
The SEC should focus more on companies like Oncolix that scam investors